As of May 2023, the EMA (European Medicines Agency) had approved several CAR T-cell therapies. Some of the approved treatments included:

  • Kymriah (tisagenlecleucel) for B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Target=CD19.
  • Yescarta (axicabtagene ciloleucel) for certain types of non-Hodgkin lymphoma, including DLBCL and primary mediastinal large B-cell lymphoma (PMBCL). Target=CD19.
  • Tocartus (brexucabtagene autoleucel) for Mantle cell lymphoma (MCL) and Acute lymphoblastic leukemia (ALL). Target=CD19.
  • Breyanzi (Isocabtagene maraleucel) – for Diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-cell lymphoma (PMBCL), High-grade B-cell lymphoma (HGBL), Follicular lymphoma (FL). Target=CD19.
  • Abecma (decablagene vicieuce) for Multiple Myeloma. Target= BCMA.
  • Carvykti (citacabitogene autoleuce) for Multiple Myeloma. Target= BCMA.

It's always essential for patients and their caregivers to discuss specific treatment options, potential benefits, and risks with their healthcare providers to make informed decisions.

Prof. Arnon Nagler’s EMA certificate, head from Sheba hospital CAR-T therapy programs.